Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)

D. Van Der Heijde; A. Deodhar; O. FitzGerald

doi:10.1136/rmdopen-2017-000582corr1

Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)

D. Van Der Heijde, A. Deodhar, O. FitzGerald

Arthritis and Rheumatic Diseases

Research output: Contribution to journal › Comment/debate › peer-review

11 Scopus citations

Abstract

van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.

Original language	English (US)
Article number	000582
Journal	RMD open
Volume	4
Issue number	1
DOIs	https://doi.org/10.1136/rmdopen-2017-000582corr1
State	Published - 2018

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology

Access to Document

10.1136/rmdopen-2017-000582corr1

Cite this

@article{12764dc0f9344e71a10b8a5a4a6712dd,

title = "Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)",

abstract = "van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.",

author = "{Van Der Heijde}, D. and A. Deodhar and O. FitzGerald",

note = "Publisher Copyright: {\textcopyright} Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.",

year = "2018",

doi = "10.1136/rmdopen-2017-000582corr1",

language = "English (US)",

volume = "4",

journal = "RMD open",

issn = "2056-5933",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Correction

T2 - 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)

AU - Van Der Heijde, D.

AU - Deodhar, A.

AU - FitzGerald, O.

N1 - Publisher Copyright: © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

PY - 2018

Y1 - 2018

N2 - van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.

AB - van der Heijde D, Deodhar A, FitzGerald O, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018;4:e000582. doi: 10.1136/rmdopen-2017-000582. Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.

UR - http://www.scopus.com/inward/record.url?scp=85051199045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051199045&partnerID=8YFLogxK

U2 - 10.1136/rmdopen-2017-000582corr1

DO - 10.1136/rmdopen-2017-000582corr1

M3 - Comment/debate

AN - SCOPUS:85051199045

SN - 2056-5933

VL - 4

JO - RMD open

JF - RMD open

IS - 1

M1 - 000582

ER -

Correction: 4-year results from the RAPID-PsA phase 3 randomised Placebo-Controlled trial of certolizumab pegol in psoriatic arthritis (RMD Open (2018) 4: (e000582). DOI: 10.1136/rmdopen-2017-000582)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this